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Purpose: To establish performance benchmarks for modern screen-
ing digital mammography and assess performance trends 
over time in U.S. community practice.
Materials and 
Methods:
This HIPAA-compliant, institutional review board–approved 
study measured the performance of digital screening mam-
mography interpreted by 359 radiologists across 95 facilities 
in six Breast Cancer Surveillance Consortium (BCSC) regis-
tries. The study included 1 682 504 digital screening mam-
mograms performed between 2007 and 2013 in 792 808 
women. Performance measures were calculated according to 
the American College of Radiology Breast Imaging Reporting 
and Data System, 5th edition, and were compared with pub-
lished benchmarks by the BCSC, the National Mammogra-
phy Database, and performance recommendations by expert 
opinion. Benchmarks were derived from the distribution of 
performance metrics across radiologists and were presented 
as 50th (median), 10th, 25th, 75th, and 90th percentiles, 
with graphic presentations using smoothed curves.
Results: Mean screening performance measures were as follows: 
abnormal interpretation rate (AIR), 11.6 (95% confidence 
interval [CI]: 11.5, 11.6); cancers detected per 1000 
screens, or cancer detection rate (CDR), 5.1 (95% CI: 
5.0, 5.2); sensitivity, 86.9% (95% CI: 86.3%, 87.6%); 
specificity, 88.9% (95% CI: 88.8%, 88.9%); false-negative 
rate per 1000 screens, 0.8 (95% CI: 0.7, 0.8); positive 
predictive value (PPV) 1, 4.4% (95% CI: 4.3%, 4.5%); 
PPV2, 25.6% (95% CI: 25.1%, 26.1%); PPV3, 28.6% 
(95% CI: 28.0%, 29.3%); cancers stage 0 or 1, 76.9%; 
minimal cancers, 57.7%; and node-negative invasive 
cancers, 79.4%. Recommended CDRs were achieved by 
92.1% of radiologists in community practice, and 97.1% 
achieved recommended ranges for sensitivity. Only 59.0% 
of radiologists achieved recommended AIRs, and only 
63.0% achieved recommended levels of specificity.
Conclusion: The majority of radiologists in the BCSC surpass cancer 
detection recommendations for screening mammography; 
however, AIRs continue to be higher than the recom-
mended rate for almost half of radiologists interpreting 
screening mammograms.
q RSNA, 2016
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The purpose of our study was to estab-
lish performance benchmarks for mod-
ern screening digital mammography 
and to assess performance trends over 
time in U.S. community practice.
Materials and Methods
Data Source
This study included six BCSC mammog-
raphy registries (Carolina Mammogra-
phy Registry, Group Health Coopera-
tive, New Hampshire Mammography 
Network, Vermont Breast Cancer Sur-
veillance System, San Francisco Mam-
mography Registry, and Metropolitan 
Chicago Breast Cancer Registry) that 
have previously been described in detail 
(14,15). In brief, each registry links its 
cancer mortality and the only screening 
test for breast cancer supported by the 
United States Preventive Services Task 
Force and the American Cancer Society 
(10,11). To improve the quality of mam-
mography, in the 1980s, the American 
College of Radiology (ACR) developed 
the Breast Imaging Reporting and Data 
System (BI-RADS) (12) and established 
a voluntary accreditation program that 
supported passage of the Mammogra-
phy Quality Standards Act by Congress 
in 1992.
Although randomized trials per-
formed in the 1960s and 1970s with 
now-outdated mammography technol-
ogy have confirmed that mammographic 
screening reduces breast cancer mor-
tality, randomized trials with mortality 
as an end point are not feasible to con-
tinue to assess either the effectiveness 
of new technology or factors associated 
with improved interpretive skills of ra-
diologists reading screening mammo-
grams. The Breast Cancer Surveillance 
Consortium (BCSC) is uniquely posi-
tioned to assess trends over the past 
2 decades in screening mammography 
performance in U.S. community prac-
tice. A decade ago, the BCSC published 
performance benchmarks for screen-
ing mammography in U.S. community 
practice (13). These metrics informed 
the ACR BI-RADS to establish perfor-
mance benchmarks for U.S. practice 
and also identified opportunities for im-
provements in future practice.
Two key changes have occurred to 
improve screening mammography per-
formance in community practice. The 
first is transition from screen-film mam-
mography to full-field digital mammog-
raphy, and the second is expansion of 
training programs to enhance the in-
terpretive skills of radiologists engaged 
in screening mammography programs. 
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Advances in Knowledge
 n Mean performance measures for 
modern digital screening mam-
mography in the Breast Cancer 
Surveillance Consortium (BCSC) 
were as follows: abnormal inter-
pretation rate (AIR), 11.6 (95% 
confidence interval [CI]: 11.5, 
11.6); cancers detected per 1000 
screens, 5.1 (95% CI: 5.0, 5.2); 
sensitivity, 86.9% (95% CI: 
86.3%, 87.6%); specificity, 
88.9% (95% CI: 88.8%, 88.9%); 
false-negative rate per 1000 
screens, 0.8 (95% CI: 0.7, 0.8); 
positive predictive value (PPV) 1, 
4.4% (95% CI: 4.3%, 4.5%); 
PPV2, 25.6% (95% CI: 25.1%, 
26.1%); PPV3, 28.6% (95% CI: 
28.0%, 29.3%).
 n Compared with prior perfor-
mance reports of screening 
mammography in the BCSC 
(1996–2008), the sensitivity of 
screening mammography has 
increased from 78.7% to 86.9%.
 n More than 92% of radiologists in 
community practice achieve rec-
ommended rates of cancers 
detected per 1000 women 
screened, and more than 97% 
achieve recommended ranges for 
sensitivity.
 n More than 40% of radiologists 
have AIRs outside the recom-
mended ranges, and more than 
37% fall below recommended 
ranges for specificity.
Implication for Patient Care
 n Efforts to develop and implement 
advanced technology and effec-
tive educational programs to 
reduce false-positive rates with-
out sacrificing improved detec-
tion of invasive node-negative 
cancers are encouraged.
More than 50 years ago, Wolfe (1) reported results in 3891 women undergoing screening 
mammography and emphasized the im-
portance of identifying small, clinically 
occult, node-negative breast cancers to 
afford women both the best options for 
treatment and the best chance for cure. 
Subsequent randomized clinical trials 
confirmed that screening mammogra-
phy significantly reduces breast cancer 
mortality (2–9).
Despite its limitations, mammog-
raphy continues to be the single most 
effective screening test to reduce breast 
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mammography data to a state tumor 
or Surveillance, Epidemiology, and End 
Results (SEER) registry, and data are 
pooled at a central Statistical Coordinat-
ing Center. Prior reports of BCSC reg-
istries and the Statistical Coordinating 
Center are available at http://www.bcsc-
research.org/publications/index.html.
Study Population
Our study included women 18 years of 
age or older who underwent at least one 
digital screening mammography exami-
nation (hereafter called “mammogram”) 
between 2007 and 2013. To measure 
performance trends over time, we also 
included previously reported data from 
the BCSC between the years 1996 and 
2008 (16). Examinations occurring 
within 9 months of a prior mammogram 
or breast ultrasonographic (US) exami-
nation were excluded to remove poten-
tial diagnostic mammograms. We also 
excluded women with breast augmenta-
tion, because we were unable to distin-
guish implant displacement views from 
diagnostic views obtained the same day.
Mammographic Data Collection 
Procedures and Definitions
Across all BCSC registries, women 
complete a questionnaire at each visit 
that includes questions about their per-
sonal history of breast cancer, family 
history of breast cancer, date of last 
mammogram, menopausal status, and 
self-reported symptoms. We calculated 
the BCSC version 1 5-year risk score, 
which estimates the probability of in-
vasive breast cancer within the next 5 
years on the basis of age, race, ethnic-
ity, family history, history of breast bi-
opsy, and breast density (17).
All BCSC registries capture BI-RADS 
assessment and recommendation cate-
gories assigned by the interpreting ra-
diologist for each mammogram. For the 
purposes of this study, we created an 
initial overall assessment for the screen-
ing examination, using the most serious 
BI-RADS assessment according to the 
following hierarchy: negative, 1; benign, 
2; probably benign, 3; needs additional 
evaluation, 0; suspicious, 4; and highly 
suggestive of malignancy, 5. We followed 
ACR BI-RADS 5th edition definitions for 
all metrics (12). For all measures except 
positive predictive value (PPV) 2 and 
PPV3, a positive mammogram was de-
fined as one with initial assessment cate-
gories 0, 3, 4, or 5. For PPV2 and PPV3, 
a positive mammogram was defined as 
one with final assessment categories 4 
or 5. As per BI-RADS audit rules, any 
mammogram with a BI-RADS 6 assess-
ment (known breast cancer) was ex-
cluded from analyses.
Women were considered to have 
breast cancer if a state tumor or SEER 
registry or pathology database indi-
cated the diagnosis of invasive breast 
carcinoma or ductal carcinoma in 
situ (DCIS) within 12 months after a 
screening mammogram and before the 
next screening mammogram.
Outcome Measurements and Statistical 
Analysis
Following ACR BI-RADS 5th edition 
definitions, a true-positive (TP) mam-
mogram was a positive mammogram 
followed by the diagnosis of breast 
cancer within 12 months. A true-nega-
tive (TN) mammogram was a negative 
mammogram followed by no diagnosis 
of breast cancer within 12 months. A 
false-positive (FP) mammogram was 
a mammogram interpreted as positive 
with no breast cancer diagnosed within 
12 months. A false-negative (FN) mam-
mogram was a negative mammogram 
followed by a diagnosis of breast can-
cer within 12 months. Cancer detection 
rate (CDR) was defined as the number 
of TP examinations divided by the total 
number of screening mammograms. FN 
rate (FNR) was defined as the number 
of FN examinations divided by the to-
tal number of screening mammograms. 
Sensitivity was calculated by dividing the 
number of TP examinations by the total 
number of examinations associated with 
cancer (TP + FN), and specificity was 
calculated by dividing the number of TN 
examinations by the total number of ex-
aminations without cancer (TN + FP).
The following three PPV calculations 
were made by using BI-RADS meth-
odology: PPV1 (probability of cancer 
following initial assessment of 0, 3, 4, or 
5), PPV2 (probability of cancer following 
a final assessment of 4 or 5), and PPV3 
(probability of cancer among patients 
with biopsy performed after final assess-
ment of 4 or 5). For screens with an ini-
tial BI-RADS assessment of 0, the final 
assessment was determined from addi-
tional imaging records up to 180 days 
after the screening examination.
Statistical Analysis
Descriptive statistics (frequencies, per-
centiles, means, and medians) were 
chosen to provide clinically relevant 
screening performance benchmarks. 
We illustrate the variability across ra-
diologists using percentile values to in-
dicate ranges that describe the middle 
50% and 80%. For example, the spec-
trum from 25th to 75th percentile 
values defines the range within which 
the middle 50% of performance was 
found, and the spectrum from 10th to 
90th percentile values defines the range 
within which the middle 80% of perfor-
mance was found.
To reduce the amount of random 
statistical variation in these data, we 
reported outcomes from radiologists 
who contributed a minimum number 
of events for each outcome, as follows: 
1000 examinations for abnormal inter-
pretation (recall) rate and CDR, 3000 
examinations for FNR, 100 abnormal 
interpretations for PPV1, 30 biopsies 
recommended for PPV2, 30 biopsies 
performed for PPV3, 30 cancer cases 
for sensitivity, 1000 noncancers for 
specificity, and 15 cancers with com-
plete information on the outcome cri-
teria for cancer measurements. We 
used graphic presentations (frequency 
distributions overlaid with percentile 
values) to display these data in an eas-
ily understandable format. All analyses 
were performed by using SAS software, 
version 9.3 (SAS Institute, Chicago, Ill), 
and all figures were produced by using 
STATA, version 12.1 (Stata, College Sta-
tion, Tex).
Results
From 2007 to 2013, 359 radiologists 
from 95 facilities across six registries 
contributed 1 682 504 digital screening 
mammograms in 792 808 women. The 
demographics of the study population 
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are comparable to those of the U.S. 
population (Table E1 [online]), al-
though the study population includes 
slightly more rural and more educated 
women, more Asian women, and fewer 
Latina women. There were no impor-
tant differences in African American 
representation or in economic status.
The mean age of women undergo-
ing screening mammography was 56.5 
years. The majority (80.4%) of screen-
ing mammograms were performed in 
women aged 40–69 years; 29.3% of 
all screening mammograms were per-
formed in women younger than 50 years 
of age, and 60.9% were performed in 
women aged 50–74 years. In women 
given a diagnosis of breast cancer, the 
majority (76.0%) had no family history 
of breast cancer, 85.0% had no personal 
history of breast cancer, and 84.9% had 
a BCSC 5-year risk of less than 2.5%. 
Breast density distributions did not dif-
fer in women with a breast cancer diag-
nosis versus in women without a breast 
cancer diagnosis (Table 1).
Mammographic Performance Measures
The mean abnormal interpretation rate 
(AIR) was 11.6% (95% confidence in-
terval [CI]: 11.5, 11.6). Of 1 682 504 ex-
aminations, 8529 breast cancers were 
diagnosed after a positive mammogram, 
for a total CDR of 5.1 (95% CI: 5.0, 5.2) 
per 1000 screening examinations. The 
invasive CDR was 3.5 cancers per 1000 
examinations, and the DCIS detection 
rate was 1.6 cancers per 1000 examina-
tions. The sensitivity of screening mam-
mography was 86.9% (95% CI: 86.3%, 
87.6%), and the specificity was 88.9% 
(95% CI: 88.8%, 88.9%). There were 
1283 FN examinations out of 1 682 504 
examinations, for an FNR of 0.8 exami-
nations per 1000 (95% CI: 0.7, 0.8). Out 
of 194 668 examinations with an initial 
BI-RADS category of 0, 3, 4, or 5, 8529 
cancers were diagnosed, for a PPV1 of 
4.4 (95% CI: 4.3, 4.5). Out of 28 785 ex-
aminations with a final BI-RADS category 
of 4 or 5, 7376 cancers were diagnosed, 
Table 1
Clinical Demographics for 1 682 504 Screening Mammographic 
Examinations
Characteristic
Total No. of 
Examinations
Total No. of 
Examinations with 
Cancer
Age group (y)
 29 957 (0.1) 7 (0.1)
 30–39 40 522 (2.4) 114 (1.2)
 40–49 448 587 (26.7) 1679 (17.1)
 50–59 505 816 (30.1) 2494 (25.4)
 60–69 396 943 (23.6) 2930 (29.9)
 70–79 209 747 (12.5) 1817 (18.5)
 80 79 932 (4.8) 771 (7.9)
Race
 White, non-Hispanic 1 125 330 (71.5) 6919 (75.3)
 Black, non-Hispanic 141 197 (9.0) 802 (8.7)
 Asian/Pacific Islander 175 281 (11.1) 973 (10.6)
 Native American 4266 (0.3) 14 (0.2)
 Latina 56 296 (3.6) 251 (2.7)
 Mixed/other 71 575 (4.5) 230 (2.5)
 Unknown 108 559 623
Family history of breast cancer
 No 1 163 946 (83.1) 6230 (76.0)
 Yes 235 882 (16.9) 1968 (24.0)
 Unknown 282 676 1614
Personal history of breast cancer
 No 1 156 765 (94.9) 5793 (85.0)
 Yes 61 628 (5.1) 1022 (15.0)
 Unknown 464 111 2997
History of prior breast biopsy
 No 1 349 949 (80.7) 6818 (69.7)
 Yes 323 567 (19.3) 2963 (30.3)
 Unknown 8988 31
Table 1 (continues)
Table 1 (continued)
Clinical Demographics for 1 682 504 Screening Mammographic 
Examinations
Characteristic
Total No. of 
Examinations
Total No. of 
Examinations with 
Cancer
Time since last mammogram
 No previous mammogram 59 766 (3.7) 300 (3.2)
 Within a year (0–11 months) 19 015 (1.2) 155 (1.7)
 1–2 Years (12–35 months) 1 388 776 (86.6) 7532 (81.6)
 +3 Years (36 months) 135 255 (8.4) 1247 (13.5)
 Unknown 79 692 578
Menopausal status
 Premenopausal 372 059 (25.7) 1602 (17.8)
 Postmenopausal 1 019 146 (70.3) 7143 (79.5)
 Surgical/other amenorrhea 57 642 (4.0) 237 (2.6)
 Unknown 233 657 830
Breast density
 Almost entirely fat 168 015 (11.1) 707 (8.4)
 Scattered fibroglandular densities 632 529 (41.9) 3605 (42.7)
 Heterogeneously dense 587 049 (38.9) 3484 (41.3)
 Extremely dense 122 496 (8.1) 641 (7.6)
 Unknown 172 415 1375
Self-reported symptoms*
 No 1 292 619 (98.3) 7413 (94.2)
 Yes 22 890 (1.7) 453 (5.8)
 Unknown 366 995 1946
5-Year risk (%)
 ,1.00 459 436 (34.5) 1361 (20.9)
 1.00–1.66 488 329 (36.6) 2434 (37.3)
 1.67–2.49 270 977 (20.3) 1746 (26.8)
 2.50–3.99 101 449 (7.6) 841 (12.9)
 4.00 12 376 (0.9) 143 (2.2)
 Unknown 349 937 3287
Note.—Data in parentheses are percentages.
* Symptoms include nipple discharge, lump, not otherwise specified, and other (not including 
pain).
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Table 2
Performance Measures for 1 682 504 Screening Digital Mammography Examinations
Measure Value*
AIR (recall rate) (%) 11.6 (11.5,11.6)
 No. of abnormal interpretations 194 668
 Total no. of examinations 1 682 504
CDR (per 1000 examinations) 5.1 (5.0, 5.2)
 No. of cancers detected 8529
 Total no. of examinations 1 682 504
Sensitivity (%) 86.9 (86.3, 87.6)
 No. of TP examinations 8529
 No. of cancers 9812
Specificity (%) 88.9 (88.8, 88.9)
 No. of TN examinations 1 486 553
 No. of noncancers 1 672 692
FNR (per 1000 examinations) 0.8 (0.7, 0.8)
 No. of FN examinations 1283
 Total no. of examinations 1 682 504
PPV1, abnormal interpretations (%) 4.4 (4.3, 4.5)
 No. of cancers 8529
 Initial BI-RADS category of 0,3,4, or 5 194 668
PPV2, biopsy recommended (%) 25.6 (25.1, 26.1)
 No. of cancers 7376
 Final BI-RADS category of 4 or 5 28 785
PPV3, biopsy performed (%)† 28.6 (28.0, 29.3)
 No. of cancers 5945
 Final BI-RADS category 4 or 5 with biopsy 20 763
* Data in parentheses are 95% CIs, which were based on Wald asymptotic confidence limits.
† Excludes Chicago.
for a PPV2 of 25.6 (95% CI: 25.1, 26.1). 
The PPV3 calculated (5945 cancers out of 
20 763 examinations with final BI-RADS 
category 4 or 5 with biopsy) was 28.6 
(95% CI: 28.0, 29.3) (Tables 2, 3).
Cancers Detected with Digital Screening 
Mammography
Of the 8529 cancers detected with 
mammography, 2644 (31%) were DCIS 
and 5885 (69%) were invasive. Of the 
invasive cancers, 38.3% were 10 mm 
or smaller, 40.2% were between 11 and 
20 mm, and 21.5% were larger than 20 
mm at time of diagnosis. The majority 
(76.9%) of all cancers were diagnosed 
at stage 0 or 1, and 4816 (57.7%) were 
minimal cancers (defined as DCIS or 
invasive cancers  10 mm). Of 5789 
cancers with known nodal status, 4599 
(79.4%) were node negative. Fifty-two 
(0.6%) of 8354 cancers were metastatic 
at the time of diagnosis (Tables 3, 4).
Radiologists Performing within 
Acceptable Ranges
Overall, radiologists performed better 
for measures of cancer detection and 
Table 3
Performance Measures for 1 682 504 Screening Digital Mammography Examinations 
from 2007 to 2013
Performance Measure 1996–2005 2004–2008 2007–2013* NMD 2008–2012†
AIR (recall rate) (%) 10.9 10.0 11.6 (11.5, 11.6) 10.0
CDR (per 1000 examinations) 4.8 4.3 5.1 (5.0, 5.2) 3.43
Sensitivity (%) 78.7 84.9 86.9 (86.3, 87.6) NA
Specificity (%) 89.5 90.3 88.9 (88.8, 88.9) NA
FNR (per 1000 examinations) 0.8 (0.7, 0.8) NA
PPV1, abnormal interpretations (%) 4.4 4.2 4.4 (4.3, 4.5) NA
PPV2, biopsy recommended (%) 25.1 23.9 25.6 (25.1, 26.1) 18.5
PPV3, biopsy performed (%) 31.8 27.9 28.6 (28.0, 29.3) 29.2
* Data in parentheses are 95% CIs, which were based on Wald asymptotic confidence limits.
† NMD = National Mammography Database, NA = not applicable.
Table 4
Characteristics of Cancers 
Detected with Digital Screening 
Mammographic Examinations
Characteristic Value
Total no. of detected cancers 8529
Cancer histologic type
 DCIS 2644 (31.0)
 Invasive 5885 (69.0)
Invasive cancer size (mm)*
 1–5 727 (12.7)
 6–10 1461 (25.6)
 11–15 1459 (25.5)
 16–20 840 (14.7)
 .20 1228 (21.5)
 Unknown 170
Minimal cancer†
 No 3527 (42.3)
 Yes 4816 (57.7)
 Unknown 186
Axillary lymph node status‡
 Negative 4599 (79.4)
 Positive 1190 (20.6)
 Unknown 96
Cancer stage
 0 2644 (31.6)
 I 3784 (45.3)
 II 1585 (19.0)
 III 289 (3.5)
 IV 52 (0.6)
 Unknown 175
Note.—Data in parentheses are percentages.
* Mean = 15.9 mm and median = 13.0 mm among 
known invasive cancer sizes.
† Defined as DCIS or invasive cancers  10 mm.
‡ Refers to invasive cancers only.
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sensitivity and worse for measures of 
recall rates and specificity (Fig 1). The 
range of sensitivities of the middle 50% 
of all radiologists was 84.8%–90.7%, 
with 97.1% of radiologists perform-
ing in the acceptable range of greater 
than 75% sensitivity. More than 92% 
of radiologists achieved the recom-
mended acceptable range of greater 
than 2.5 cancers detected per 1000 
examinations, with 50% of radiologists 
performing within the range of 3.7–5.7 
cancers detected per 1000 examina-
tions. The range of recall, or abnormal 
interpretation, rates of the middle 50% 
of all radiologists was 8.4–14.7, with 
only 59.0% of radiologists performing 
within the recommended acceptable 
range of 5%–12%. For specificity, 50% 
of radiologists performed within the 
range of 85.8%–92.0% and only 63.0% 
met the acceptable range of 88%–95% 
specificity.
For 194 radiologists contributing 
3000 or more examinations, 50% had 
FNRs between 0.5 and 1.0 per 1000 
examinations (Fig 2). A large percent-
age (62%) of radiologists did not meet 
the recommended range of 20%–40% 
PPV2 (cancers diagnosed in all exami-
nations assessed as BI-RADS category 
4 or 5). Roughly one in four radiologists 
had a PPV2 of less than 20% (Fig 3). 
The range of PPV3 values for half of 
all radiologists was 23.0–39.0. Twenty-
five percent of radiologists performed 
below this range and 25% performed 
higher than this range.
For radiologists who detected 15 or 
more cancers, 50% identified between 
73% and 84% of cancers at stage 0 
or 1. In addition, 50% of radiologists 
Figure 1
Figure 1: Graphs show common performance measures. Sensitivity was restricted to final readers with 30 or more cancers (n = 104). Specificity was restricted to final  
readers with 1000 or more noncancers (n = 249). CDR was restricted to final readers with 1000 or more examinations (n = 242). Recall rate was restricted to final readers 
with 1000 or more examinations (n = 242). Max = maximum, min = minimum, p10 = 10th percentile, p25 = 25th percentile, p75 = 75th percentile, p90 = 90th percentile.
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Figure 2
Figure 3
Figure 3: Graph shows PPVs. PPV1 was restricted to final readers with 100 
or more abnormal examinations (n = 255). PPV2 was restricted to final readers 
with 30 or more recommended biopsies (n = 172). PPV3 was restricted to final 
readers with 30 or more biopsies performed (n = 125). Max = maximum, min = 
minimum, p10 = 10th percentile, p25 = 25th percentile, p75 = 75th percentile, 
p90 = 90th percentile.
Figure 2: Graph 
shows FNR, which 
was restricted to final 
readers with 3000  
or more examinations 
(n = 194). Max = max-
imum, min = minimum, 
p10 = 10th percentile, 
p25 = 25th percentile, 
p75 = 75th percentile, 
p90 = 90th percentile.
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Figure 4
diagnosed between 75% and 87% of 
cancers while they were node negative 
(Fig 4). For the 111 radiologists who 
diagnosed at least 15 invasive cancers 
in the study period, 50% identified in-
vasive cancers in the range of 13.6–
16.8 mm (Fig 5).
Discussion
National performance benchmarks for 
screening mammography were pub-
lished previously by the BCSC in 2006 
and were subsequently updated in 2008, 
on the basis of examinations performed 
from 1996 to 2005 and from 2004 to 
2008, respectively (17). Our study pro-
vides more recent estimates of modern 
digital screening mammography per-
formance in the United States on the 
basis of examinations performed from 
2007 to 2013. We restricted our study 
to digital mammography to provide 
performance measures most relevant 
for current clinical practice. Among the 
overall statistics and variation across 
radiologists provided in our study, a few 
key findings stand out.
First, the sensitivity for modern 
digital screening mammography in the 
BCSC is higher than prior BCSC re-
ports from the pre-digital era (86.9% 
vs 78.7%). This likely reflects the im-
proved performance of digital mam-
mography compared with screen-film 
mammography in women with dense 
breast tissue (18,19), which includes 
almost half of women undergoing 
screening mammography. In particu-
lar, more cases of DCIS are diagnosed 
with modern screening mammogra-
phy than in the prior BCSC reports 
(21% of cancers diagnosed in 2004–
2008 BCSC examinations were DCIS, 
compared with 31% of cancers di-
agnosed in our current study) (13). 
The rate of invasive cancers per 1000 
examinations in our study was 3.5 
invasive cancers detected per 1000 
women screened, compared with the 
prior 1996–2005 BCSC report of 3.7 
invasive cancers detected per 1000 
women screened. Details of cancers 
detected are not available from the 
NMD, precluding comparison.
Second, the CDR of 5.1 cancers 
per 1000 examinations in our study 
is significantly higher than that re-
ported by the NMD (3.43 per 1000 
[95% CI: 3.2, 3.7]). This may in part 
be explained by the improved ability 
of the BCSC to collect pathology data 
from multiple sources, including state 
tumor registries, compared with the 
NMD, which relies on data collected 
by radiology facilities alone. The total 
rate of all cancers (those detected and 
those not detected with mammogra-
phy) was 5.9 per 1000 (95% CI: 5.7, 
6.0). The total rate of cancers is not 
Figure 4: Graphs show cancer characteristics. Percentage minimal cancer 
was restricted to final readers with 15 or more detected cancers (n = 140) of 
known size. Percentage of cancers that were node negative was restricted to fi-
nal readers with 15 or more detected invasive cancers (n = 111) of known size. 
Percentage of cancers that were stage 0 or 1 was restricted to final readers 
with 15 or more detected cancers (n = 143) of known stage. Max = maximum, 
min = minimum, p10 = 10th percentile, p25 = 25th percentile, p75 = 75th 
percentile, p90 = 90th percentile.
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available from the NMD, precluding 
comparison.
Last, the mean AIR in our study 
of 11.6% was higher than those in the 
2005 and 2008 BCSC reports (10.9% 
and 10.0%, respectively) and higher 
than the 10.0% rate reported by the 
NMD (14,20). This is particularly con-
cerning, given that recall rates have 
continually failed to meet the recom-
mendations of the ACR and other ex-
pert panels going back to the initial 
BCSC report in 2005, despite calls for 
attention to this matter (13). Increas-
ing access to tomosynthesis imaging 
for screening could yield improve-
ments in recall rates, with current 
data suggesting that tomosynthesis 
can reduce recalls by 15%–20% (21–
24)—down from initial estimates of 
30%–40% (25,26). However, extreme 
variation across facilities and individ-
uals threatens this gain. For instance, 
four of the 13 sites in the largest U.S. 
multicenter report had recall rates 
for mammograms performed with 
tomosynthesis that were well above 
the recommended rates for digital 
mammography alone (23). Adequate 
education and training of new users 
must be matched with ongoing quality 
assurance efforts if tomosynthesis is to 
achieve its full benefits in community 
clinical practice.
A notable limitation of our study 
was that, despite the large sample size, 
not all radiologists contributed suffi-
cient interpretations to be included in 
all performance measures. Given the 
low rates of cancers in average-risk 
screening populations combined with 
the relatively low numbers of mam-
mograms required for credentialing in 
the United States, accurate estimates 
of sensitivity necessarily exclude many 
radiologists in practice. Hence, radi-
ologists with lower numbers of mam-
mograms may not achieve the same 
high sensitivities we found in the 104 
of 359 radiologists who contributed 
at least 1000 screening mammogram 
interpretations during the study pe-
riod. Individual radiologists and breast 
imaging facilities can nonetheless use 
our results to gauge their performance 
against this national cohort.
In summary, we found that the 
majority of radiologists in U.S. com-
munity practice surpass most perfor-
mance recommendations of the ACR; 
however, AIRs continue to be higher 
than the recommended rate for al-
most half of radiologists interpreting 
screening mammograms. Programs to 
support second reviews of mammo-
grams recalled by radiologists known 
to “overcall” mammograms could be 
implemented. The second reviews of 
the recalls could be performed by radi-
ologists with documented high perfor-
mance for both recall and CDRs. The 
resource investment would be man-
ageable for most practices, as it would 
require second reads of roughly only 
11%–20% of mammograms read by the 
radiologists with poor specificity, rather 
than second reads of all mammograms. 
The latter approach (second reads of 
all mammograms) would be required 
for radiologists who performed below 
benchmarks for CDRs. In our study, we 
found this was a relatively uncommon 
scenario.
Mammography screening programs 
stand out as unique in imaging because 
they are required by law to perform 
practice audits. However, currently 
there are no requirements for additional 
training or practice restrictions for ra-
diologists performing below minimal 
performance standards. Carney et al 
(27) have shown the potential positive 
impacts on our patients and health care 
expenditures if all radiologists were to 
meet minimally acceptable standards 
of performance. Yet achieving this end 
will likely require remedial or restrictive 
action to be taken regarding subpar per-
formers. Whether we are ready to take 
this next step in quality assurance and 
cost containment in screening mammog-
raphy warrants careful consideration.
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